Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 2, 2012, Pages 473-482

  Pettipher, Roy ^a   Vinall, Shân L ^a   Xue, Luzheng ^a   Speight, Graham ^a   Townsend, Elizabeth R ^a   Gazi, Lucien ^a   Whelan, Cliff J ^b   Armer, Richard E ^a   Payton, Mark A ^a   Hunter, Michael G ^a  

^a Oxagen Ltd   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; COMPLEMENT COMPONENT C5A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; EOTAXIN; IMMUNOGLOBULIN E; INDOLEACETIC ACID DERIVATIVE; OC 000459; PROSTAGLANDIN D2; PROSTANOID RECEPTOR; PROTEIN D PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; UNOPROSTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CELL SHAPE; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EOSINOPHIL COUNT; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IC 50; LEUKOCYTE ACTIVATION; LOEFFLER PNEUMONIA; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ANIMALS; APOPTOSIS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; CALCIUM SIGNALING; CELL MEMBRANE; CELL SHAPE; CHEMOKINE CCL11; CHEMOTAXIS; CHO CELLS; COMPLEMENT C5A; CRICETINAE; CULTURE MEDIA, CONDITIONED; EOSINOPHILIA; EOSINOPHILS; GUINEA PIGS; HUMANS; INDOLEACETIC ACIDS; INTERLEUKIN-13; INTERLEUKIN-5; LEUKOTRIENE B4; LYMPHOCYTE ACTIVATION; MAST CELLS; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDIN D2; PULMONARY EOSINOPHILIA; QUINOLINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECOMBINANT PROTEINS; TH2 CELLS; TRANSFECTION;

EID: 84856006564     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187203     Document Type: Article

References (39)

1. Bain G, Lorrain DS, Stebbins KJ, Broadhead AR, Santini AM, Prodanovich P, Darlington J, King CD, Lee C, Baccei C, et al. (2011) Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther 338:290-301.
2. Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Payton M, Pearce Collins L, Pettipher R, Steiner J, Perkins M (2012) A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma. Clin Exp Allergy 42:38-48.
3. Boehme SA, Chen EP, Franz-Bacon K, Sásik R, Sprague LJ, Ly TW, Hardiman G, and Bacon KB (2009a) Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol 21:1-17.
4. Boehme SA, Franz-Bacon K, Chen EP, Sásik R, Sprague LJ, Ly TW, Hardiman G, and Bacon KB (2009b) A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 21:81-93.
5. Bryan SA, Jose PJ, Topping JR, Wilhelm R, Soderberg C, Kertesz D, Barnes PJ, Williams TJ, Hansel TT, and Sabroe I (2002) Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med 165:1602-1609. (Pubitemid 34693939)
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, et al. (2004) Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593.
8. 2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 67:959-962.
9. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, and Urade Y (2002) Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 168: 443-449. (Pubitemid 34014147)
10. Gauvreau GM, Watson RM, and O'Byrne PM (1999) Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 160:640-647. (Pubitemid 29380685)
11. 2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes. Prostaglandins Other Lipid Mediat 75:153-167.
12. + Th2 lymphocytes in response to mast cell supernatants. Immunology 119:362-368.
13. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, and Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168:981-985. (Pubitemid 34094458)
14. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seventransmembrane receptor CRTH2. J Exp Med 193:255-261.
15. Khan LN, Kon OM, Macfarlane AJ, Meng Q, Ying S, Barnes NC, and Kay AB (2000) Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am J Respir Crit Care Med 162:1377-1382.
16. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129:1627-1631.
17. Lukacs NW, Berlin AA, Franz-Bacon K, Sásik R, Sprague LJ, Ly TW, Hardiman G, Boehme SA, and Bacon KB (2008) CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol 295: L767-L779.
18. Maezawa Y, Nakajima H, Seto Y, Suto A, Kumano K, Kubo S, Karasuyama H, Saito Y, and Iwamoto I (2004) IgE-dependent enhancement of Th2 cell-mediated allergic inflammation in the airways. Clin Exp Immunol 135:12-18. (Pubitemid 38067922)
19. Middlemiss D, Ashton MR, Boyd EA, Brookfield FA, and Pettipher ER (2005) inventors; Oxagen Limited, assignee. Use of CRTH2 antagonist compounds in therapy. World patent WO-2005044260. 2005 May 19.
20. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98:1942-1948.
21. 2 into human airways during acute antigen challenge. N Engl J Med 315:800-804.
22. Nomiya R, Okano M, Fujiwara T, Maeda M, Kimura Y, Kino K, Yokoyama M, Hirai H, Nagata K, Hara T, et al. (2008) CRTH2 plays an essential role in the pathophysiology of Cryj1-induced pollinosis in mice. J Immunol 180:5680-5688.
23. Oiwa M, Satoh T, Watanabe M, Niwa H, Hirai H, Nakamura M, and Yokozeki H (2008) CRTH2-dependent, STAT6-independent induction of cedar pollen dermatitis. Clin Exp Allergy 38:1357-1366. (Pubitemid 352019661)
24. 1 and CRTH2 in promoting allergic responses. Br J Pharmacol 153 (Suppl 1):S191-S199.
25. 1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 6:313-325.
26. Rossi GA, Crimi E, Lantero S, Gianiorio P, Oddera S, Crimi P, and Brusasco V (1991) Late-phase asthmatic reaction to inhaled allergen is associated with early recruitment of eosinophils in the airways. Am Rev Respir Dis 144:379-383.
27. 2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177:2621-2629.
28. 2 receptor, CRTH2. Br J Pharmacol 137:1163-1172.
29. Shichijo M, Sugimoto H, Nagao K, Inbe H, Encinas JA, Takeshita K, Bacon KB, and Gantner F (2003) Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. J Pharmacol Exp Ther 307:518-525. (Pubitemid 37310664)
30. Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, and Kay AB (1997) Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 52:447-452. (Pubitemid 27278143)
31. 2/CRTH2 increases allergic inflammation in mouse. J Immunol 174:3703-3708.
32. Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, and Lorrain DS (2010) Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 638:142-149.
33. 2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res 8:16.
34. Ulven T and Kostenis E (2010) Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat 20:1505-1530.
35. Vinall SL, Townsend ER, and Pettipher R (2007) A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+CD4+ T helper type 2 lymphocytes. Immunology 121:577-584. (Pubitemid 47030095)
36. 2-induced airway eosinophilia in guinea-pigs is independent of interleukin-5. Inflamm Res 58:103-108.
37. Williams CM and Galli SJ (2000) Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 192:455-462. (Pubitemid 30629171)
38. Xue L, Barrow A, and Pettipher R (2009) Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182:7580-7586.
39. 2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 175:6531-6536.